Non-Communicable Diseases Account For 27% Of Deaths In Kenya

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, has signed a Memorandum of Understanding (MoU) with Mission for Essential Drugs and Supplies (MEDS) to further expand the impact of Boehringer Ingelheim’s ‘Access to Healthcare’ program. The partnership aims to improve access to affordable, life-saving medication for patients living with type 2 diabetes and hypertension in Kenya while strengthening local healthcare capacity through strategic collaborations.
‘Access to Healthcare’ is an end-to-end patient support program by Boehringer Ingelheim, in partnership with local health stakeholders, offering equitable healthcare access for underserved communities in Kenya. Launched in September 2022, the program aims to enhance disease management, provide medical treatments through subsidized pricing models, and ensure patient adherence to medication for non-communicable diseases such as hypertension and type 2 diabetes. The program is set to expand across the region in the coming years.
Recent research on Non-Communicable Diseases (NCDs) In Kenya, NCDs are estimated to account for 27% of all deaths.[1] As of December 2024, Boehringer Ingelheim’s Access to Healthcare program has engaged more than 200 physicians, enrolled over 1,500 patients, and collaborated with 15 healthcare facilities in Kenya.
In addition to providing access to leading medications at subsidized costs, both parties will also work together to raise awareness of type 2 diabetes and hypertension in the community through ongoing campaigns.
Speaking at the signing ceremony in Nairobi, Derek O’Leary, Regional Managing Director at Boehringer Ingelheim in India, the Middle East, Turkey, and Africa (IMETA), said: “At Boehringer Ingelheim, we believe that access to quality healthcare is a fundamental right. Our ‘Access to Healthcare’ program is designed to bridge the gap for underserved communities, ensuring that patients receive life-saving treatments at subsidized costs. This partnership with MEDS is a game-changer in our mission to combat the growing burden of non-communicable diseases in Kenya. By working together, we are delivering hope, improving lives, and building a more resilient healthcare system for the future to transform lives for generations.”
Hale Asikoglu-Erkol, Head of Sustainable Development for Generations at Boehringer Ingelheim in IMETA, added: “Boehringer Ingelheim’s ‘Sustainable Development for Generations’ framework incorporates initiatives we have been implementing for many years aligning with the UN Sustainable Development Goals. We believe that sustainable healthcare solutions require long-term commitment, strategic partnerships, and a deep understanding of local needs. The MoU with MEDS will help us in our ambition to expand access to healthcare for people in underserved communities and enable a healthier, sustainable, and more equitable future for patients in Kenya.”
Also present during the signing ceremony, Dr. Stephen Kigera, on behalf of MEDS Management said: “At MEDS, we are committed to providing underserved communities in Kenya with medications that will improve their health outcomes. Through this partnership, we hope to be able to provide eligible type 2 diabetes and hypertension patients with the latest innovations in treatment from Boehringer Ingelheim. We also hope to raise awareness of these diseases to encourage early diagnosis and treatment in efforts to preserve the quality of life for patients in Kenya.”
Boehringer Ingelheim’s Sustainable Development for Generations framework is committed to creating value in areas of unmet medical need to enable a healthier, sustainable, and more equitable future. By 2030, Boehringer aims to expand access to healthcare for 50 million people in underserved communities, investing 35 billion EUR in health innovation and research to tackle non-communicable diseases and an additional 250 million EUR in partnerships to combat emerging infectious diseases.
Read Also: Pwani Oil Moves To Arrest The Red Eye Disease In Kilifi
About Soko Directory Team
Soko Directory is a Financial and Markets digital portal that tracks brands, listed firms on the NSE, SMEs and trend setters in the markets eco-system.Find us on Facebook: facebook.com/SokoDirectory and on Twitter: twitter.com/SokoDirectory
- January 2026 (220)
- February 2026 (243)
- March 2026 (126)
- January 2025 (119)
- February 2025 (191)
- March 2025 (212)
- April 2025 (193)
- May 2025 (161)
- June 2025 (157)
- July 2025 (227)
- August 2025 (211)
- September 2025 (270)
- October 2025 (297)
- November 2025 (230)
- December 2025 (219)
- January 2024 (238)
- February 2024 (227)
- March 2024 (190)
- April 2024 (133)
- May 2024 (157)
- June 2024 (145)
- July 2024 (136)
- August 2024 (154)
- September 2024 (212)
- October 2024 (255)
- November 2024 (196)
- December 2024 (143)
- January 2023 (182)
- February 2023 (203)
- March 2023 (322)
- April 2023 (297)
- May 2023 (267)
- June 2023 (214)
- July 2023 (212)
- August 2023 (257)
- September 2023 (237)
- October 2023 (264)
- November 2023 (286)
- December 2023 (177)
- January 2022 (293)
- February 2022 (329)
- March 2022 (358)
- April 2022 (292)
- May 2022 (271)
- June 2022 (232)
- July 2022 (278)
- August 2022 (253)
- September 2022 (246)
- October 2022 (196)
- November 2022 (232)
- December 2022 (167)
- January 2021 (182)
- February 2021 (227)
- March 2021 (325)
- April 2021 (259)
- May 2021 (285)
- June 2021 (272)
- July 2021 (277)
- August 2021 (232)
- September 2021 (271)
- October 2021 (304)
- November 2021 (364)
- December 2021 (249)
- January 2020 (272)
- February 2020 (310)
- March 2020 (390)
- April 2020 (321)
- May 2020 (335)
- June 2020 (327)
- July 2020 (333)
- August 2020 (276)
- September 2020 (214)
- October 2020 (233)
- November 2020 (242)
- December 2020 (187)
- January 2019 (251)
- February 2019 (215)
- March 2019 (283)
- April 2019 (254)
- May 2019 (269)
- June 2019 (249)
- July 2019 (335)
- August 2019 (293)
- September 2019 (306)
- October 2019 (313)
- November 2019 (362)
- December 2019 (318)
- January 2018 (291)
- February 2018 (213)
- March 2018 (275)
- April 2018 (223)
- May 2018 (235)
- June 2018 (176)
- July 2018 (256)
- August 2018 (247)
- September 2018 (255)
- October 2018 (282)
- November 2018 (282)
- December 2018 (184)
- January 2017 (183)
- February 2017 (194)
- March 2017 (207)
- April 2017 (104)
- May 2017 (169)
- June 2017 (205)
- July 2017 (189)
- August 2017 (195)
- September 2017 (186)
- October 2017 (235)
- November 2017 (253)
- December 2017 (266)
- January 2016 (164)
- February 2016 (165)
- March 2016 (189)
- April 2016 (143)
- May 2016 (245)
- June 2016 (182)
- July 2016 (271)
- August 2016 (247)
- September 2016 (233)
- October 2016 (191)
- November 2016 (243)
- December 2016 (153)
- January 2015 (1)
- February 2015 (4)
- March 2015 (164)
- April 2015 (107)
- May 2015 (116)
- June 2015 (119)
- July 2015 (145)
- August 2015 (157)
- September 2015 (186)
- October 2015 (169)
- November 2015 (173)
- December 2015 (205)
- March 2014 (2)
- March 2013 (10)
- June 2013 (1)
- March 2012 (7)
- April 2012 (15)
- May 2012 (1)
- July 2012 (1)
- August 2012 (4)
- October 2012 (2)
- November 2012 (2)
- December 2012 (1)
